Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

915
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
915
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

698
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
698
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

180
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
180

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating Young Children With Fractures for Child Abuse: Report From the AAP.

American family physician·2026
Same author

Resuscitation After Drowning in Children: Updated Guidelines From the AHA and AAP.

American family physician·2026
Same author

Management of Chronic Constipation: Guidelines From the American Society of Colon and Rectal Surgeons.

American family physician·2026
Same author

Management of Tinnitus: Guidelines From the VA/DoD.

American family physician·2026
Same author

Acute Migraine Treatment: Guidelines From the International Headache Society.

American family physician·2026
Same author

Management of Elevated Blood Pressure in Acute Care: Statement From the American Heart Association.

American family physician·2026
Same journal

Primary Care at the Center of America's Mental Health Landscape.

Primary care·2026
Same journal

We Care, and We Will Listen.

Primary care·2026
Same journal

Addressing Sexual Health in Primary Care.

Primary care·2026
Same journal

Diagnosis and Management of Eating Disorders in Adolescents and Young Adults.

Primary care·2026
Same journal

Management of Concomitant Mental Health Conditions in Older Adults with Cognitive Impairment.

Primary care·2026
Same journal

Nonpharmacologic Management of Insomnia Disorder in Primary Care.

Primary care·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2025

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.0K

Thromboembolic Disease.

Michael J Arnold1

  • 1Department of Family Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 40814, USA.

Primary Care
|January 26, 2024
PubMed
Summary
This summary is machine-generated.

Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, ranges from mild to severe. Statin therapy may offer some protection, and Well's criteria guide diagnosis for non-emergency cases.

Keywords:
Deep vein thrombosisDiagnosisManagementPreventionPrimary carePulmonary embolismVenous thromboembolism

More Related Videos

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.2K
Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
06:45

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

13.2K

Related Experiment Videos

Last Updated: Jul 4, 2025

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.0K
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

17.2K
Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
06:45

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

13.2K

Area of Science:

  • Cardiology
  • Hematology

Background:

  • Venous thromboembolism (VTE) includes deep vein thrombosis and pulmonary embolism, presenting with varied severity.
  • Cardiovascular risk factors often overlap with VTE risk factors.
  • Statin therapy may provide a degree of VTE risk reduction.

Purpose of the Study:

  • To review the clinical presentation, risk factors, diagnostic approaches, and treatment strategies for VTE.
  • To highlight the role of statins in potentially mitigating VTE risk.
  • To outline the use of clinical prediction scores for VTE diagnosis.

Main Methods:

  • Review of existing literature on VTE.
  • Analysis of risk factors, including cardiovascular associations.
  • Evaluation of diagnostic criteria, such as Well's criteria.
  • Summary of current treatment modalities for VTE.

Main Results:

  • VTE presents on a spectrum from subtle symptoms to emergencies.
  • Shared risk factors exist between cardiovascular disease and VTE.
  • Statin use is associated with a potential reduction in VTE risk.
  • Well's criteria are instrumental in guiding diagnostic testing for non-life-threatening VTE.
  • Anticoagulant therapy is the primary treatment for VTE.
  • Thrombolytic therapy is reserved for severe, life- or limb-threatening presentations.

Conclusions:

  • VTE management requires a nuanced approach based on clinical presentation and risk factors.
  • Understanding overlapping risk factors and potential therapeutic benefits, like statins, is crucial.
  • Appropriate diagnostic strategies, guided by clinical scores, ensure timely and effective treatment.